Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Beta-d-xylopyranoside, (3beta,15alpha,16alpha,23r,24s)-16,23-16,24-diepoxy-15,25-dihydroxy-9,19-cyclolanostan-3-yl
1. 27994-11-2
2. Cimigenol Xyloside
3. Cimigoside
4. 1cw26vcp4h
5. Chebi:70246
6. (2s,3r,4s,5r)-2-[[(1s,2r,3s,4r,7r,9s,12r,14s,17r,18r,19r,21r,22s)-2-hydroxy-22-(2-hydroxypropan-2-yl)-3,8,8,17,19-pentamethyl-23,24-dioxaheptacyclo[19.2.1.01,18.03,17.04,14.07,12.012,14]tetracosan-9-yl]oxy]oxane-3,4,5-triol
7. Cimigenoside Xyloside
8. Unii-1cw26vcp4h
9. Cimigenol 3-beta-d-xylopyranoside
10. Cimicifugol Xyloside
11. Chembl218613
12. Dtxsid0033334
13. Cimigenol-3-o-beta-d-xylopyranoside
14. Zinc49942441
15. Akos030573698
16. .beta.-d-xylopyranoside, (3.beta.,15.alpha.,16.alpha.,23r,24s)-16,23:16,24-diepoxy-15,25-dihydroxy-9,19-cyclolanostan-3-yl
17. Beta-d-xylopyranoside, (3beta,15alpha,16alpha,23r,24s)-16,23:16,24-diepoxy-15,25-dihydroxy-9,19-cyclolanostan-3-yl
18. Cimigenol 3-o-.beta.-d-xylopyranoside
19. Q27138585
20. Cimigenol-3-o-.beta.-d-xyloside (24s) (constituent Of Black Cohosh) [dsc]
| Molecular Weight | 620.8 g/mol |
|---|---|
| Molecular Formula | C35H56O9 |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 3 |
| Exact Mass | 620.39243336 g/mol |
| Monoisotopic Mass | 620.39243336 g/mol |
| Topological Polar Surface Area | 138 Ų |
| Heavy Atom Count | 44 |
| Formal Charge | 0 |
| Complexity | 1210 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 17 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Cimigenoside manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cimigenoside, including repackagers and relabelers. The FDA regulates Cimigenoside manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cimigenoside API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Cimigenoside supplier is an individual or a company that provides Cimigenoside active pharmaceutical ingredient (API) or Cimigenoside finished formulations upon request. The Cimigenoside suppliers may include Cimigenoside API manufacturers, exporters, distributors and traders.
Cimigenoside Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cimigenoside GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cimigenoside GMP manufacturer or Cimigenoside GMP API supplier for your needs.
A Cimigenoside CoA (Certificate of Analysis) is a formal document that attests to Cimigenoside's compliance with Cimigenoside specifications and serves as a tool for batch-level quality control.
Cimigenoside CoA mostly includes findings from lab analyses of a specific batch. For each Cimigenoside CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cimigenoside may be tested according to a variety of international standards, such as European Pharmacopoeia (Cimigenoside EP), Cimigenoside JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cimigenoside USP).
LOOKING FOR A SUPPLIER?
